Cost of Revenue of Ernexa Therapeutics Inc. from 30 Sep 2022 to 31 Dec 2024

Taxonomy & unit
us-gaap: USD
Description
The aggregate cost of goods produced and sold and services rendered during the reporting period.
Summary
Ernexa Therapeutics Inc. quarterly and annual Cost of Revenue in USD history and change rate from 30 Sep 2022 to 31 Dec 2024.
  • Ernexa Therapeutics Inc. Cost of Revenue for the quarter ending 31 Dec 2024 was $0.
  • Ernexa Therapeutics Inc. Cost of Revenue for the twelve months ending 31 Dec 2024 was $96,000.
  • Ernexa Therapeutics Inc. annual Cost of Revenue for 2024 was $96,000, a 59% decline from 2023.
  • Ernexa Therapeutics Inc. annual Cost of Revenue for 2023 was $236,000.
Source SEC data
View on sec.gov
Cost of Revenue, Trailing 12 Months (USD)
Cost of Revenue, Quarterly (USD)
Cost of Revenue, YoY Quarterly Change (%)
Cost of Revenue, Annual (USD)
Cost of Revenue, YoY Annual Change (%)

Ernexa Therapeutics Inc. Quarterly Cost of Revenue (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2024 $96,000 $0 01 Oct 2024 31 Dec 2024 10-K 13 Mar 2026 2025 FY
Q3 2024 $60,000 -$180,000 -150% 01 Jul 2024 30 Sep 2024 10-Q 12 Nov 2024 2024 Q3
Q2 2024 $95,000 01 Apr 2024 30 Jun 2024 10-Q 13 Aug 2025 2025 Q2
Q1 2024 $61,000 +$11,000 +22% 01 Jan 2024 31 Mar 2024 10-Q 07 May 2025 2025 Q1
Q3 2023 $120,000 +$120,000 01 Jul 2023 30 Sep 2023 10-Q 12 Nov 2024 2024 Q3
Q1 2023 $50,000 01 Jan 2023 31 Mar 2023 10-Q 14 May 2024 2024 Q1
Q3 2022 $0 01 Jul 2022 30 Sep 2022 10-Q 13 Nov 2023 2023 Q3

Ernexa Therapeutics Inc. Annual Cost of Revenue (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $96,000 -$140,000 -59% 01 Jan 2024 31 Dec 2024 10-K 13 Mar 2026 2025 FY
2023 $236,000 +$236,000 01 Jan 2023 31 Dec 2023 10-K 12 Mar 2025 2024 FY
2022 $0 01 Jan 2022 31 Dec 2022 10-K 14 Mar 2024 2023 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.